SCHEMBL16020336

SCHEMBL16020336

CCc1cnn(CCNC(=O)OC(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.41
▸ GFER P55789 1/20 0.41
▸ MALT1 Q9UDY8 1/20 0.40
▸ DRD2 P14416 2/20 0.40
▸ PARG Q86W56 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39
▸ STK17B O94768 1/20 0.39
▸ STK17A Q9UEE5 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ BTK Q06187 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ NCOR2 Q9Y618 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ SIGMAR1 Q99720 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27322432 0.86 ALDH1A1 (0.41) ALDH1A1GFERMALT1DRD2PARG
SCHEMBL13975444 0.84 LMNA (0.47) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL29828529 0.83 SIGMAR1 (0.40) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL18764807 0.83 DRD2 (0.41) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL24613337 0.83 KMT2A (0.43) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL13740008 0.83 ALDH1A1 (0.41) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL16899828 0.83 ALDH1A1 (0.41) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL19558618 0.83 ALDH1A1 (0.41) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL19902326 0.82 L3MBTL1 (0.43) ALDH1A1GFERMALT1DRD2TDP1
SCHEMBL17454460 0.82 L3MBTL1 (0.41) ALDH1A1GFERMALT1DRD2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9808466-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 2017-11-07 — — US disclosed
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2016-10-13 — — US disclosed
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 ALDH1A1 4625/4885GFER 4442/4885MALT1 711/4885
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 ALDH1A1 4625/4885GFER 4442/4885MALT1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback